Hyperactivation by genomic mutations in oncogenic growth-signaling molecules, such as MAPK, PI3K, and the epidermal growth factor receptor (EGFR), can also enhance CD274 expression in malignant melanoma, NSCLC, and gallbladder cancer [32,33,34]. Here, EGFR is linked to melanoma.